PERSONAL INFORMATION
Name：Huang Zhenglan
Gender：Female
CONTACT INFORMATION
Email：zhenglan@cqmu.edu.cn
EDUCATION EXPERIENCE
2002.9-2007.6: bachelor degree, major in laboratory medicine, Centre South University
2007.9-2010.6: master degree, major in laboratory medicine, Chongqing Medical University
2010.9-2013.6: doctor degree, major in laboratory medicine, Chongqing Medical University
WORKING EXPERIENCE
2013.7-2016.9: lecturer, Department of Clinical Hematology, School of Laboratory Medicine, Chongqing Medical University.
2016.9 to present: vice professor, Department of Clinical Hematology, School of Laboratory Medicine, Chongqing Medical University.
RESEARCH INTERESTS
The mechanisms for p190BCR-ABL and p210BCR-ABL to induce different leukemia. The specific mechanism of imatinib resistance in CML patients.
HONOR & AWARDS
Qiande backbone teacher of Chongqing Medical University
PUBLICATIONS
1. Qin Ru, Wang Teng, He Wei, Wei Wei, Liu Suotian, Gao Miao, Huang Zhenglan. Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190BCR-ABL. Cell Communication and Signaling, 2023, 21(27):1-18.
2. Zeng Dachuan, Gao Miao, Zheng Renren, Qin Run, He Wei, Liu Suotian, Wei Wei, Huang Zhenglan. The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification. Experimental Hematology & Oncology, 2022; 11(1):33.
3. Jiang Guoyun, Huang Zhenglan, Yuan Ying, Tao Kun, Feng Wenli. Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells. Journal of Hematology & Oncology, 2021, 14:139.
4. Li Qian, Huang Zhenglan, Peng Yuhang, Wang Xin, Jiang Guoyun, Wang Teng, Mou Ke, Feng Wenli. RanBP3 Regulates Proliferation, Apoptosis and Chemosensitivity of Chronic Myeloid Leukemia Cells via Mediating SMAD2/3 and ERK1/2 Nuclear Transport. Front. Oncol., 2021, 11:698410.
5. Yang Hao, Zhou Hongyan, Huang Zhenglan, Tao Kun, Huang Ningshu, Peng Zhi, Feng Wenli. Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides. Cancer letters, 2020, 482: 44-55.
6. Luo Zhenhong, Gao Miao, Huang Ningshu, Wang Xin, Yang Zesong, Yang Hao, Huang Zhenglan, Feng Wenli. Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells. J Exp Clin Cancer Res, 2019, 38(1): 224.
7. Huang Ningshu, Huang Zhenglan, Gao Miao, Luo Zhenhong, Zhou Fangzhu, Liu Lin, Xiao Qing, Xin Wang and Wenli Feng. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases. J Exp Clin Cancer Res, 2018, 37: 62-75.
8. Li Hui, Huang Zhenglan, Gao Miao, Huang Ningshu, Luo Zhenhong, Shen Huawei, Wang Xin, Wang Teng, Hu Jing, Feng Wenli. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo. J Exp Clin Cancer Res, 2016, 35(1): 134-134.
9. Huang Zheng-Lan, Gao Miao, Li Qian-Yin, Tao Kun, Xiao Qing, Cao Wei-Xi, Feng Wen-Li. Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus. Oncotarget, 2013, 4(12): 2249-2260.
10. Huang Zheng-Lan, Gao Miao, Ji Mao-Sheng, Tao Kun, Xiao Qing, Zhong Liang, Zeng Jian-Ming, Feng Wen-Li. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization. Amino Acids, 2013, 44(2): 461-472.
